Unum Therapeutics announced that the United States Patent and Trademark Office, or USPTO, has issued U.S. patent 10,144,770. The patent covers design and use of the chimeric antibody-coupled T-cell receptor, or ACTR, platform technology that enables an engineered immune cell to be targeted via an antibody to attack certain cell types, including cancer cells. An ACTR-expressing T cell offers a number of potential advantages over alternative cell therapy approaches and clinical proof-of-concept for the ACTR technology has been demonstrated in two independent clinical trials sponsored by Unum Therapeutics. ACTR therapeutic programs targeting non-Hodgkin lymphoma, multiple myeloma, and HER2+ advanced cancers are currently in early stages of clinical testing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.